<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926289</url>
  </required_header>
  <id_info>
    <org_study_id>502.550</org_study_id>
    <secondary_id>2008-007711-32</secondary_id>
    <nct_id>NCT00926289</nct_id>
  </id_info>
  <brief_title>Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension</brief_title>
  <official_title>A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension (Systolic Blood Pressure (SBP) &gt;=160 mmHg and Diastolic Blood Pressure (DBP) &gt;=100 mmHg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to demonstrate that the fixed-dose combination of
      T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood
      Pressure(SBP) compared to the monotherapy of T80 in patients with grade 2 or grade 3
      hypertension (SBP&gt;=160 mmHg and Diastolic Blood Pressure(DBP)&gt;=100 mmHg).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7</measure>
    <time_frame>Baseline and Week 7</time_frame>
    <description>The SBP value at baseline was subtracted from the SBP value at Week 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Seated Trough Cuff SBP to Week 5</measure>
    <time_frame>Baseline and Week 5</time_frame>
    <description>The SBP value at baseline was subtracted from the SBP value at Week 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Seated Trough Cuff SBP to Week 3</measure>
    <time_frame>Baseline and Week 3</time_frame>
    <description>The SBP value at baseline was subtracted from the SBP value at Week 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Seated Trough Cuff Diastolic Blood Pressure (DBP) to Week 7</measure>
    <time_frame>Baseline and Week 7</time_frame>
    <description>The DBP value at baseline was subtracted from the DBP value at Week 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With SBP Control (SBP &lt; 140 mmHg) at Week 7</measure>
    <time_frame>Week 7 timepoint</time_frame>
    <description>SBP control is defined as SBP &lt; 140 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With SBP Control (SBP &lt; 140 mmHg) at Week 5</measure>
    <time_frame>Week 5 timepoint</time_frame>
    <description>SBP control is defined as SBP &lt; 140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With SBP Control (SBP &lt; 140 mmHg) at Week 3</measure>
    <time_frame>Week 3 timepoint</time_frame>
    <description>SBP control is defined as SBP &lt; 140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With DBP Control (DBP &lt; 90 mmHg) at Week 7</measure>
    <time_frame>Week 7 timepoint</time_frame>
    <description>DBP control is defined as DBP&lt;90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With DBP Control (DBP &lt; 90 mmHg) at Week 5</measure>
    <time_frame>Week 5 timepoint</time_frame>
    <description>DBP control is defined as DBP&lt;90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With DBP Control (DBP &lt; 90 mmHg) at Week 3</measure>
    <time_frame>Week 3 timepoint</time_frame>
    <description>DBP control is defined as DBP&lt;90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Blood Pressure (BP) Control at Week 7</measure>
    <time_frame>Week 7 timepoint</time_frame>
    <description>BP control is defined as SBP&lt;140 mmHg and DBP &lt; 90 mmHg and is adjusted for baseline SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With BP Control at Week 7</measure>
    <time_frame>Week 7 timepoint</time_frame>
    <description>BP control is defined as SBP&lt;140 mmHg and DBP &lt; 90 mmHg and is adjusted for baseline DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Systolic Blood Pressure (SBP) Response at Week 7</measure>
    <time_frame>Week 7 timepoint</time_frame>
    <description>SBP response is defined as SBP&lt;140 mmHg or a reduction of &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With DBP Response at Week 7</measure>
    <time_frame>Week 7 timepoint</time_frame>
    <description>DBP response is defined as DBP&lt;90 mmHg or a reduction of &gt;= 10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Categories at Week 7</measure>
    <time_frame>Week 7 timepoint</time_frame>
    <description>BP categories comprise:
BP optimal (SBP &lt;120 mmHg and DBP &lt;80 mmHg)
BP normal (SBP &lt;130 mmHg and DBP &lt;85 mmHg but not 'optimal')
BP high normal (SBP &lt;140 mmHg and DBP &lt;90 mmHg but not 'normal')
Grade 1 hypertension (SBP &lt;160 mmHg and DBP &lt;100 mmHg but not 'high normal')
Grade 2 hypertension (SBP &lt;180 mmHg and DBP &lt;110 mmHg but not 'Grade 1 hypertension')
Grade 3 hypertension (SBP ≥180 mmHg or DBP ≥110 mmHg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">894</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan/hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan80mg/Hydrochlorothiazide25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan 80mg</description>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan 80mg</description>
    <arm_group_label>Telmisartan/hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide25mg</description>
    <arm_group_label>Telmisartan/hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Ability to provide written informed consent in accordance with Good Clinical Practice
             and local legislation;

          2. Age 18 years or older;

          3. Patients with grade 2 or grade 3 hypertension as defined SBP&gt;=160 mmHg and DBP&gt;=100
             mmHg at randomization

          4. Ability to stop any current antihypertensive therapy without unacceptable risk to the
             patient (Investigator's discretion)

        Exclusion criteria:

          1. Pre-menopausal women (last menstruation &lt;=1 year prior to signing informed consent)
             who: a) are not surgically sterile; or b) are nursing, or c) are pregnant, or d) are
             of childbearing potential and are NOT practicing acceptable methods of birth control,
             or do NOT plan to continue practicing an acceptable method throughout the trial. The
             only acceptable methods of birth control are: Intra-Uterine Device (IUD), Oral
             contraceptives, Implantable or injectable contraceptives, Estrogen patch Hormonal
             birth control should have been in use for at least three months before the study and
             continue at least until the next menstrual period after completing the study.

          2. Night shift workers who routinely sleep during the daytime and whose work hours
             include midnight to 4:00 a.m.

          3. Known or suspected secondary hypertension (e.g., renal artery stenosis
             orphaeochromocytoma)

          4. Mean in-clinic seated cuff SBP&gt;= 200 mmHg and/or DBP &gt;=120 mmHg

          5. Renal dysfunction as defined by the following laboratory parameters: Serum creatinine
             &gt;3.0 mg/dL (or &gt;265 umol/L) and/or known creatinine clearance of &lt;30 ml/min and/or
             clinical markers of severe renal impairment.

          6. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney,
             post-renal transplant patients or patients with only one kidney

          7. Clinically relevant hypokalemia or hyperkalemia (i.e., &lt;3.5 mmol/L or &gt;5.5 mmol/L, may
             be rechecked for suspected error in result)

          8. Uncorrected sodium or volume depletion

          9. Primary aldosteronism.

         10. Hereditary fructose intolerance

         11. Biliary obstructive disorders (e.g., cholestasis) or hepatic insufficiency

         12. Congestive heart failure New York Heart Association functional class Congestive Heart
             Failure III-IV (Refer to Appendix 10.3)

         13. Contra-indication to a placebo run-in period (e.g., stroke with-in the past 6 months,
             myocardial infarction, cardiac surgery, percutaneous transluminal coronary
             angioplasty, unstable angina or coronary artery bypass graft within the past 3 months
             prior to start of run in period)

         14. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or
             other clinically relevant cardiac arrhythmias as determined by the Investigator

         15. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease,
             aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve

         16. Patients whose diabetes has not been stable and controlled for at least the past 3
             months as defined by an Glycosylated Hemoglobin &gt;=10%

         17. Patients who have previously experienced symptoms characteristic of angioedema during
             treatment with ACE inhibitors or angiotensin-II receptor antagonists

         18. History of drug or alcohol dependency within 6 months prior to signing the informed
             consent form

         19. Concomitant administration of any medications known to affect blood pressure, except
             medications allowed by the protocol

         20. Any investigational drug therapy within 1 month of signing the informed consent

         21. Known hypersensitivity to any component of the trial drugs (telmisartan,
             hydrochlorothiazide, or placebo)

         22. History of non-compliance or inability to comply with prescribed medications or
             protocol procedures (less than 80% or more than 120%, especially during run-in)

         23. Any other clinical condition which, in the opinion of the investigator, would not
             allow safe completion of the protocol and safe administration of the trial medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>502.550.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Iberia</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35910 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35911 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.35906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou, Guangdong Province</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>QingDao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3302D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aigrefeuille S/Maine</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3305I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aix-en-Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3305G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aubagne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3301H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Briollay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3301K Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3302I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corsept</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3302C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Montagne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louvigné de Bais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3303D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3303F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3304D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3304F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3304J Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murs Erigne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3301I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murs-Erigne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3302E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3301E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parcay-les-Pins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roquevaire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3301F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Segre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3302G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Aubin les Châteaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3306F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Jouan des Guerets</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thouars</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.3301J Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vihiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.99501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.99502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.99503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.99504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.99505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.99506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.99507 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.99508 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.82010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baia Mare Maramures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.40008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tg. Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502.550.07010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>China</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Korea, Republic of</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <results_first_submitted>April 20, 2011</results_first_submitted>
  <results_first_submitted_qc>April 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 24, 2011</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>894 patients were entered (randomised) into the study; however, of these, 6 were not treated. Therefore 888 patients actually entered into treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan 40/80 mg</title>
          <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Telmisartan 40/80 mg + HCTZ (Hydrochlorothiazide) 12.5/25 mg</title>
          <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="294">Number of treated patients</participants>
                <participants group_id="P2" count="594">Number of treated patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="558"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan 40/80 mg</title>
          <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
          <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="294"/>
            <count group_id="B2" value="594"/>
            <count group_id="B3" value="888"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="11.9"/>
                    <measurement group_id="B2" value="56.8" spread="11.3"/>
                    <measurement group_id="B3" value="57.0" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7</title>
        <description>The SBP value at baseline was subtracted from the SBP value at Week 7.</description>
        <time_frame>Baseline and Week 7</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7</title>
          <description>The SBP value at baseline was subtracted from the SBP value at Week 7.</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="541"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="0.88"/>
                    <measurement group_id="O2" value="-37.0" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Fixed effects of treatment, week, treatment-by-week interaction, country with the continuous covariates of baseline and baseline-by-week interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>-6.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Seated Trough Cuff SBP to Week 5</title>
        <description>The SBP value at baseline was subtracted from the SBP value at Week 5.</description>
        <time_frame>Baseline and Week 5</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Seated Trough Cuff SBP to Week 5</title>
          <description>The SBP value at baseline was subtracted from the SBP value at Week 5.</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="0.86"/>
                    <measurement group_id="O2" value="-35.8" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Fixed effects of treatment, week, treatment-by-week interaction, country with the continuous covariates of baseline and baseline-by-week interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>-5.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Seated Trough Cuff SBP to Week 3</title>
        <description>The SBP value at baseline was subtracted from the SBP value at Week 3.</description>
        <time_frame>Baseline and Week 3</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Seated Trough Cuff SBP to Week 3</title>
          <description>The SBP value at baseline was subtracted from the SBP value at Week 3.</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" spread="0.87"/>
                    <measurement group_id="O2" value="-33.3" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Fixed effects of treatment, week, treatment-by-week interaction, country with the continuous covariates of baseline and baseline-by-week interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>-4.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Seated Trough Cuff Diastolic Blood Pressure (DBP) to Week 7</title>
        <description>The DBP value at baseline was subtracted from the DBP value at Week 7.</description>
        <time_frame>Baseline and Week 7</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Seated Trough Cuff Diastolic Blood Pressure (DBP) to Week 7</title>
          <description>The DBP value at baseline was subtracted from the DBP value at Week 7.</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="541"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" spread="0.55"/>
                    <measurement group_id="O2" value="-18.6" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Fixed effects of treatment, week, treatment-by-week interaction, country with the continuous covariates of baseline and baseline-by-week interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>-1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With SBP Control (SBP &lt; 140 mmHg) at Week 7</title>
        <description>SBP control is defined as SBP &lt; 140 mmHg.</description>
        <time_frame>Week 7 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With SBP Control (SBP &lt; 140 mmHg) at Week 7</title>
          <description>SBP control is defined as SBP &lt; 140 mmHg.</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline, treatment and country as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.74</ci_lower_limit>
            <ci_upper_limit>3.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With SBP Control (SBP &lt; 140 mmHg) at Week 5</title>
        <description>SBP control is defined as SBP &lt; 140 mmHg</description>
        <time_frame>Week 5 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With SBP Control (SBP &lt; 140 mmHg) at Week 5</title>
          <description>SBP control is defined as SBP &lt; 140 mmHg</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline, treatment and country as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With SBP Control (SBP &lt; 140 mmHg) at Week 3</title>
        <description>SBP control is defined as SBP &lt; 140 mmHg</description>
        <time_frame>Week 3 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With SBP Control (SBP &lt; 140 mmHg) at Week 3</title>
          <description>SBP control is defined as SBP &lt; 140 mmHg</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline, treatment and country as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.60</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With DBP Control (DBP &lt; 90 mmHg) at Week 7</title>
        <description>DBP control is defined as DBP&lt;90 mmHg</description>
        <time_frame>Week 7 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With DBP Control (DBP &lt; 90 mmHg) at Week 7</title>
          <description>DBP control is defined as DBP&lt;90 mmHg</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline, treatment and country as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With DBP Control (DBP &lt; 90 mmHg) at Week 5</title>
        <description>DBP control is defined as DBP&lt;90 mmHg</description>
        <time_frame>Week 5 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With DBP Control (DBP &lt; 90 mmHg) at Week 5</title>
          <description>DBP control is defined as DBP&lt;90 mmHg</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline, treatment and country as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.48</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With DBP Control (DBP &lt; 90 mmHg) at Week 3</title>
        <description>DBP control is defined as DBP&lt;90 mmHg</description>
        <time_frame>Week 3 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With DBP Control (DBP &lt; 90 mmHg) at Week 3</title>
          <description>DBP control is defined as DBP&lt;90 mmHg</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline and fixed effect country</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Blood Pressure (BP) Control at Week 7</title>
        <description>BP control is defined as SBP&lt;140 mmHg and DBP &lt; 90 mmHg and is adjusted for baseline SBP</description>
        <time_frame>Week 7 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Blood Pressure (BP) Control at Week 7</title>
          <description>BP control is defined as SBP&lt;140 mmHg and DBP &lt; 90 mmHg and is adjusted for baseline SBP</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline (SBP), treatment and country as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With BP Control at Week 7</title>
        <description>BP control is defined as SBP&lt;140 mmHg and DBP &lt; 90 mmHg and is adjusted for baseline DBP</description>
        <time_frame>Week 7 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With BP Control at Week 7</title>
          <description>BP control is defined as SBP&lt;140 mmHg and DBP &lt; 90 mmHg and is adjusted for baseline DBP</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline (DBP), treatment and country as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.78</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Systolic Blood Pressure (SBP) Response at Week 7</title>
        <description>SBP response is defined as SBP&lt;140 mmHg or a reduction of &gt;= 15 mmHg</description>
        <time_frame>Week 7 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Systolic Blood Pressure (SBP) Response at Week 7</title>
          <description>SBP response is defined as SBP&lt;140 mmHg or a reduction of &gt;= 15 mmHg</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline, treatment and country as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With DBP Response at Week 7</title>
        <description>DBP response is defined as DBP&lt;90 mmHg or a reduction of &gt;= 10 mmHg</description>
        <time_frame>Week 7 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With DBP Response at Week 7</title>
          <description>DBP response is defined as DBP&lt;90 mmHg or a reduction of &gt;= 10 mmHg</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustment for continuous covariate of baseline, treatment and country as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.57</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Categories at Week 7</title>
        <description>BP categories comprise:
BP optimal (SBP &lt;120 mmHg and DBP &lt;80 mmHg)
BP normal (SBP &lt;130 mmHg and DBP &lt;85 mmHg but not ‘optimal’)
BP high normal (SBP &lt;140 mmHg and DBP &lt;90 mmHg but not ‘normal’)
Grade 1 hypertension (SBP &lt;160 mmHg and DBP &lt;100 mmHg but not ‘high normal’)
Grade 2 hypertension (SBP &lt;180 mmHg and DBP &lt;110 mmHg but not ‘Grade 1 hypertension’)
Grade 3 hypertension (SBP ≥180 mmHg or DBP ≥110 mmHg)</description>
        <time_frame>Week 7 timepoint</time_frame>
        <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40/80 mg</title>
            <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
            <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>BP Categories at Week 7</title>
          <description>BP categories comprise:
BP optimal (SBP &lt;120 mmHg and DBP &lt;80 mmHg)
BP normal (SBP &lt;130 mmHg and DBP &lt;85 mmHg but not ‘optimal’)
BP high normal (SBP &lt;140 mmHg and DBP &lt;90 mmHg but not ‘normal’)
Grade 1 hypertension (SBP &lt;160 mmHg and DBP &lt;100 mmHg but not ‘high normal’)
Grade 2 hypertension (SBP &lt;180 mmHg and DBP &lt;110 mmHg but not ‘Grade 1 hypertension’)
Grade 3 hypertension (SBP ≥180 mmHg or DBP ≥110 mmHg)</description>
          <population>The Full Analysis Set (FAS) included all patients in the treated set who provide a baseline trough cuff BP measurement and at least one seated trough cuff BP measurement following titration to target therapy (T80+H25 or T80), taken on the same arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BP optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP high normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T80+HCTZ25 versus T80 monotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Van Elteren test stratified for country</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan 40/80 mg</title>
          <description>Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Telmisartan 40/80 mg + HCTZ 12.5/25 mg</title>
          <description>fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Meddra 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

